Articles

Assessing Outcomes and Socioeconomic and Racial Disparities Using Data from the National Cancer Institute’s SEER Program

A small study suggests that in select patients with long-lasting disease stabilization, elective discontinuation of CDK4/6 inhibitors is feasible. Read More ›

Evaluating the Effectiveness and Toxicities Associated with Novel Oral Agents Palbociclib and Ribociclib to Understand the Influence of Regimen Changes on Disease Progression

A large retrospective cohort population-based study demonstrated a disproportionate elevation of breast cancer–specific and all-cause mortality among African American women. Read More ›

A Comprehensive Literature Review of Available Real-World Evidence Evaluating CDK4/6 Inhibitors in Patients with HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

For the treatment of patients with HR-positive/HER2-negative metastatic breast cancer, targeting CDK4/6 represents a novel, effective, and safe therapeutic approach in combination with hormone therapy. Read More ›

In CDK4/6 Inhibitor and Endocrine Therapy–Resistant Breast Cancer, Co-Targeting CDK4/6 and AKT with Endocrine Therapy Prevents Progression

CDK4/6 inhibitors were associated with improved outcomes in HR-positive/HER2-negative advanced metastatic breast cancer. Read More ›

Nivolumab Combined with Chemotherapy Improves Survival Outcome in Patients with Advanced Gastric/Esophageal Cancers

Study results suggest the potential of clinical development of estrogen receptor, CDK4/6, and AKT co-targeting strategies after progression on a CDK4/6 inhibitor and endocrine therapy combination, and in tumors showing high phospho-AKT levels. Read More ›

Second-Line Pembrolizumab Therapy Conveys Survival Benefit in Patients with Advanced Esophageal Cancer

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer. Read More ›

ASCO Clinical Practice Guidelines for Clinician Management of Patients with Advanced Esophageal Cancer

Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer. Read More ›

CheckMate 648 Study Data Indicate Improved Overall Survival for Patients with Advanced Esophageal Squamous-Cell Carcinoma Treated with Nivolumab and Ipilimumab or Chemotherapy

An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma. Read More ›

Immune Checkpoint Analysis in Gastric Adenocarcinoma

Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study. Read More ›